Form D · Biotechnology
Neoantigenics, Inc.
Charlottesville, VA · CIK 0001589704
Offering snapshot reported Feb 24, 2015 · SEC filing
- Reported sold
- $3.03M Offering amount: $3.03M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 12, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 24, 2015 | Initial | $3,025,713 | No comparison | 4 | SEC filing |
| Oct 22, 2013 | Initial | $112,200 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-234626
Source: Form D, filed Feb 24, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fred Eshelman | Director |
| John C. Herr | Director, Executive, Promoter |
| Edward J. Leary | Executive, Promoter |
| Brian A. Pollok | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1000 Research Park Blvd. Suite 103
Charlottesville, VA, 22911
Charlottesville, VA, 22911